Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New natural gel for bacterial vaginosis passes first safety check

NCT ID NCT07514416

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 4 times

Summary

This early-stage study tests whether LCFA-01, a natural gel containing oleic acid, is safe and comfortable when placed in the vagina. Thirty healthy women aged 18-40 will use the gel and be monitored for side effects, discomfort, and how much of the product enters the bloodstream. The goal is to gather safety data before testing it as a treatment for bacterial vaginosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females aged 18 to 40 years (inclusive) who are pre-menopausal at the time of providing informed consent * You should be generally healthy, with no major past illnesses, and your doctor should not see anything concerning during your check-up before starting the study. * Your BMI (a measure of weight and height) must be between 18.0 and 34.9. * You must be a non-smoker or only an occasional smoker. If you smoke 2 cigarettes or less per week (or similar, like vaping or cigars), you may still join, depending on the study doctor's decision. * Your blood and urine test results should be normal, unless the study doctor decides that a slightly abnormal result is not a problem. * You must test negative for common sexually transmitted infections (STIs) at the screening visit. * You must not be pregnant at Screening or when you join the study. * You should have regular periods, unless you are using hormonal birth control that stops your periods. If you do have regular periods, you will join the study within 5 days after your period ends. * You must agree not to use any vaginal products (like creams, gels, or suppositories) during the study. * You must agree not to have sexual intercourse during the study and also avoid: receptive oral sex anal sex vaginal sex toys * If you can become pregnant, you must use a reliable form of birth control starting from Screening until 90 days after your last dose of the study product.(Using only condoms is not enough.) * You must be willing and able to come to all required study visits. * You must be willing to sign a consent form after the study has been explained to you, including how your samples may be stored for future research. Exclusion Criteria: * Women who currently have moderate or severe vaginal symptoms (such as pain, itching, burning, or unusual discharge) at the Screening visit cannot join the study. * Women with physical or mental health conditions that, in the opinion of the study doctor, would make it difficult for them to follow the study rules or finish the study will not be able to participate. * Women who have had certain surgeries, such as: * removal of the uterus (full or partial hysterectomy) major surgeries on the cervix, vagina, or uterus (for example: cervical cone biopsy,removal of the cervix, or major uterine surgery) * cannot participate because these procedures may change the vaginal or reproductive anatomy, which could affect study results. * Women with certain medical conditions, including: a. Serious diseases of the vagina, cervix, or uterus, such as: * cancers of the female reproductive system * endometriosis * chronic or recurrent vaginal infections b. Uncontrolled genital herpes, meaning they had at least one active outbreak in the past 6 months. c. Serious health problems such as: heart disease or a past heart attack chronic lung disease (like COPD) chronic kidney failure severe liver disease (cirrhosis) or any other serious condition that the study doctor believes would make it unsafe to join the study. d. Any condition that would require using steroid medicines inside the genital area during the study. (Steroid creams used on the skin, inhalers, or nose sprays are allowed.) e. A yeast infection (vulvovaginal candidiasis) found during Screening. f. Repeated episodes of bacterial vaginosis (BV), meaning two or more episodes in the past year. * Women who have ever had an autoimmune disease cannot join the study. * Autoimmune diseases happen when the body's immune system attacks its own tissues. Examples include: Hashimoto's thyroid disease Pernicious anemia Addison's disease Rheumatoid arthritis Lupus Multiple sclerosis Myasthenia gravis Grave's disease Celiac disease Psoriasis Sarcoidosis Scleroderma Diabetes (Type 1) * Also, anyone who shows signs of an autoimmune disease now, or is taking medicines that weaken the immune system, may be excluded based on the study doctor's judgment. * Women who were diagnosed with a cervicovaginal infection (such as gonorrhea, chlamydia, trichomonas, or Mycoplasma genitalium) within 30 days before Screening cannot join. * Women who had an infection requiring antibiotics or antifungal medicines within 14 days before Screening cannot join. * Women who used any vaginal cleaning practices in the past 14 days cannot participate. This includes: vaginal douching using products to clean, wash, dry, or "freshen" the vagina * Women who test positive for syphilis at Screening cannot join. * Women who have HIV cannot participate, whether the infection is treated, untreated, or well controlled. * Women who have chronic hepatitis B infection cannot join the study. * Women who are currently taking medicine to treat hepatitis C cannot participate. * Women who have used long-acting investigational medicines, such as injectable HIV prevention products (PrEP), within the past year cannot join. * Women who are using a non-hormonal IUD, like the copper T IUD, or a hormonal vaginal ring, cannot take part in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial vaginosis treatment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Allied Health Hub Morayfield

    Brisbane, Queensland, 4506, Australia